Waters Corporation has reached an agreement with BD to combine with BD's BDS Business. The companies executed a mutual confidentiality agreement in March 2025, and subsequent discussions led to Waters submitting a preliminary non-binding indication of interest. The proposal included a structure aimed at providing cash proceeds to BD sufficient to maintain or potentially reduce BD's net leverage following the transaction. Both companies anticipate strong revenue and cost synergy opportunities from the combination, particularly in areas such as cross-selling Waters products in research markets and promoting LC-MS in clinical diagnostics.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Waters Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-015384), on January 16, 2026, and is solely responsible for the information contained therein.